| 8.74 -0.04 (-0.46%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.72 | 1-year : | 12.53 |
| Resists | First : | 9.18 | Second : | 10.72 |
| Pivot price | 8.13  |
|||
| Supports | First : | 8.05 | Second : | 7.34 |
| MAs | MA(5) : | 8.71 |
MA(20) : | 8.01 |
| MA(100) : | 8.1  |
MA(250) : | 7.76 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 82.2 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 9.92 | Low : | 4.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FENC ] has closed below upper band by 15.9%. Bollinger Bands are 59.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.1 - 9.15 | 9.15 - 9.19 |
| Low: | 8.5 - 8.56 | 8.56 - 8.61 |
| Close: | 8.65 - 8.74 | 8.74 - 8.82 |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fri, 20 Feb 2026
Fennec Pharmaceuticals presents real-world data showing PEDMARK feasible, well tolerated in adults with head & neck cancer - TradingView
Fri, 20 Feb 2026
Cancer drug timing tweak shows promise for preserving hearing - Stock Titan
Thu, 12 Feb 2026
B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target By Investing.com - Investing.com Australia
Sat, 27 Dec 2025
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) - The Manila Times
Sun, 21 Dec 2025
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC) - Seeking Alpha
Tue, 09 Dec 2025
Fennec Pharmaceuticals Inc Initiates Clinical Study on PEDMARK® - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 44.1 (%) |
| Shares Short | 742 (K) |
| Shares Short P.Month | 859 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -17.9 % |
| Operating Margin | -1.6 % |
| Return on Assets (ttm) | -5.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 78.6 % |
| Gross Profit (p.s.) | 1.05 |
| Sales Per Share | 1.13 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -33.62 |
| PEG Ratio | 0 |
| Price to Book value | -54.63 |
| Price to Sales | 7.69 |
| Price to Cash Flow | -37.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|